All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View GvHD content recommended for you
MSCs in GvHD and key MSC-FFM safety data
Do you know... Which mechanism best describes how mesenchymal stromal cells (MSCs) exert therapeutic effects in GvHD?
Graft-versus-host disease (GvHD) remains a major complication following allogeneic hematopoietic stem cell transplantation. Mesenchymal stromal cells (MSCs) have been studied as a potential therapy due to their immunomodulatory and anti-inflammatory properties. MSC-FFM, a standardized, pooled bone marrow-derived MSC product, has been evaluated in patients with refractory acute GvHD across multiple real-world cohorts.
Our educational mini-module reviews the mechanism of action of MSCs in GvHD and key safety data for MSC-FFM.
This educational resource is independently supported by Medac. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
